Distinct DME patterns seen on OCT

Article

Optical coherence tomography (OCT) is valuable in managing diabetic macular oedema (DME), more so than fluorescein angiography, in which the degree of leakage is not correlated with visual acuity and outcomes, according to Peter Kaiser, MD.

Optical coherence tomography (OCT) is valuable in managing diabetic macular oedema (DME), more so than fluorescein angiography, in which the degree of leakage is not correlated with visual acuity and outcomes, according to Peter Kaiser, MD. In addition, angiography does not show vitreoretinal abnormalities that may require a different treatment.

OCT provides a retinal thickness map that correlates well with leakage clinically, fluorescein leakage, and more importantly, with decreased visual acuity. The maps can be used to track progression and treatment efficacy, according to Dr Kaiser, of the Cole Eye Institute, Cleveland Clinic, Ohio, US.

The OCT single scan tomograms identify specific morphologic patterns in patients with DME; these six different patterns indicate different prognoses, requiring different management.

The sponge-like pattern is the one most commonly seen in which the inner layers of the retina appear to be compressed as the result of fluid absorption, and which responds well to laser treatment.

Cystoid macular oedema, characterized by cysts that grow and coalesce and are associated with worse visual acuity than with the sponge-like pattern, responds to steroids and anti-VEGF drugs.

Serous retinal detachment without posterior hyaloidal traction is characterized by serous fluid in the fovea not seen on ophthalmoscopy; treatment and absorption of the fluid often leads to the hard exudates deposits in the subretinal space.

Posterior hyaloidal traction leading to DME seems to be a distinct subgroup of patients. The traction is subtle but can be identified by sheen on clinical examination. Traction can cause a traction retinal detachment in a few patients. If there is traction that is more tangential resulting from the hyaloidal traction, it can be very subtle.

A retinal detachment can occur without traction; this does not respond to laser or medical therapy but requires vitrectomy.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.